此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis

2019年10月7日 更新者:Medtronic Cardiovascular

Medtronic MDT-2111 CoreValve Japan 23mm Study

The primary objective of the present trial is to demonstrate the safety and effectiveness of the MDT-2111 in the treatment of symptomatic severe aortic stenosis in subjects with small aortic annuli and deemed difficult for surgical operation.

研究概览

地位

完全的

详细说明

The purpose of this trial is to evaluate the effectiveness and safety of the MDT-2111 TAV system in subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention. The primary endpoint is a composite of functional effectiveness as measured by improvement of at least 1 New York Heart Association (NYHA) class from baseline to 6 months and anatomical effectiveness as measured by Effective Orifice Area (EOA) ≥1.0 cm² at 6 months.

研究类型

介入性

注册 (实际的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Kanagawa
      • Kamakura、Kanagawa、日本
        • Shonan Kamakura General Hospital
    • Osaka
      • Suita、Osaka、日本
        • Osaka University Hospital
      • Suita、Osaka、日本
        • National Cerebral and Cardiovascular Center
    • Saitama
      • Hidaka、Saitama、日本
        • Saitama Medical University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Subject must have co-morbidities such that one cardiologist and one cardiac surgeon agree that medical factors preclude operation, based on a conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement.
  2. Subject has senile degenerative aortic valve stenosis with:

    mean gradient > 40 mmHg or jet velocity greater than 4.0 m/s by either resting or dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac catheterization (either resting or dobutamine stress), AND an initial aortic valve area of ≤ 0.8 cm² (or aortic valve area index ≤ 0.5 cm²/m²) by resting echocardiogram.

  3. Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class Class III or greater. If screening committee agrees the eligibility of a patient with class II , based on medical factors, he/she can be enrolled.
  4. Patient has been informed of the nature of the trial and has signed an Informed Consent Form.
  5. Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed.

Exclusion Criteria:

  1. Evidence of an acute myocardial infarction ≤ 30 days prior to the intended treatment.
  2. Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the procedure.
  3. Blood dyscrasias as defined:

    • Leukopenia (WBC count < 1,000 cells/mm³)
    • Thrombocytopenia (platelet count <50,000 cells/mm³)
    • History of bleeding diathesis or coagulopathy
    • Hypercoagulable states
  4. Untreated clinically significant coronary artery disease requiring revascularization.
  5. Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
  6. Need for emergency surgery for any reason.
  7. Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% as measured by resting echocardiogram.
  8. Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack(TIA).
  9. End stage renal disease requiring chronic dialysis.
  10. GI bleeding within the past 3 months.
  11. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:

    • Aspirin
    • Ticlopidine
    • Heparin
    • Contrast media
    • Nitinol (titanium and nickel alloy)
  12. Ongoing sepsis, including active endocarditis.
  13. Subject refuses a blood transfusion.
  14. Life expectancy < 12 months due to associated non-cardiac co-morbid conditions.
  15. Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent.
  16. Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
  17. Currently participating in an investigational drug or another device trial. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
  18. Symptomatic carotid or vertebral artery disease.
  19. Native aortic annulus size < 18 mm or > 20 mm per the screening diagnostic imaging.
  20. Pre-existing prosthetic heart valve in any position.
  21. Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation).
  22. Mitral regurgitation (moderate to severe) or severe tricuspid regurgitation.
  23. Moderate to severe mitral stenosis.
  24. Hypertrophic obstructive cardiomyopathy.
  25. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
  26. Severe basal septal hypertrophy with an outflow gradient.
  27. Ascending aorta diameter > 34 mm
  28. Congenital bicuspid or unicuspid valve verified by echocardiography.
  29. For patients with native coronary artery dependent circulation:

    • Sinus of valsalva width < 25 mm OR
    • Height of the left or right coronary sinus of valsalva (to the tubular aorta) < 15mm.
  30. Femoral or iliac artery of the first choice corresponding to any one of the following:

    • Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70°.
    • Vessel diameter of femoral or iliac artery is less than 6 mm.
    • Aorta has severe calcification, excess tortuosity or severe atherosclerosis.
    • Transarterial access not able to accommodate an 18Fr sheath.
  31. Subclavian artery of the second choice corresponding to any one of the following:

    • Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70° (in the case of left subclavian artery) and 30° (in the case of right subclavian artery).
    • Vessel diameter of subclavian artery is less than 6 mm.
    • Transarterial access not able to accommodate an 18Fr sheath.
  32. Direct Aortic Artery as third line choice of access. Patients are excluded from Direct Aortic access if:

    • Access site is less than 6 cm from the aortic valve basal plane
    • Access site has calcification or porcelain aorta
    • Access site and delivery trajectory contain RIMA or patent RIMA graft

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MDT-2111 TAVI 23 mm
Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA).
大体时间:baseline and 6 months
The primary endpoint is a composite of functional effectiveness as measured by improvement of at least 1 NYHA class from baseline to 6 months and anatomical effectiveness as measured by Effective Orifice Area (EOA) ≥1.0 cm² at 6 months.
baseline and 6 months

次要结果测量

结果测量
措施说明
大体时间
New York Heart Classification (NYHA) Over Time
大体时间:30 days

NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity.

Class II: Subjects with cardiac disease resulting in slight limitation of physical activity.

Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.

Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.

30 days
New York Heart Classification (NYHA) Over Time
大体时间:6 months

NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity.

Class II: Subjects with cardiac disease resulting in slight limitation of physical activity.

Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.

Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.

6 months
New York Heart Classification (NYHA) Over Time
大体时间:12 months

NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity.

Class II: Subjects with cardiac disease resulting in slight limitation of physical activity.

Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.

Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.

12 months
New York Heart Classification (NYHA) Over Time
大体时间:24 months

NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Subject with cardiac disease but without resulting limitations of physical activity.

Class II: Subjects with cardiac disease resulting in slight limitation of physical activity.

Class III: Subjects with cardiac disease resulting in marked limitation of physical activity.

Class IV: Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort.

24 months
主要不良心脑血管事件 (MACCE)
大体时间:0天到30天

MACCE 被定义为以下各项的组合:

  • 全因死亡
  • 心肌梗塞 (MI)
  • 所有中风,和
  • 再介入(定义为任何心脏手术或经皮再介入导管手术,用于修复、改变或调整或更换先前植入的瓣膜)
0天到30天
主要不良心脑血管事件 (MACCE)
大体时间:0天至6个月

MACCE 被定义为以下各项的组合:

  • 全因死亡
  • 心肌梗塞 (MI)
  • 所有中风,和
  • 再介入(定义为任何心脏手术或经皮再介入导管手术,用于修复、改变或调整或更换先前植入的瓣膜)
0天至6个月
主要不良心脑血管事件 (MACCE)
大体时间:0天到12个月

MACCE 被定义为以下各项的组合:

  • 全因死亡
  • 心肌梗塞 (MI)
  • 所有中风,和
  • 再介入(定义为任何心脏手术或经皮再介入导管手术,用于修复、改变或调整或更换先前植入的瓣膜)
0天到12个月
主要不良心脑血管事件 (MACCE)
大体时间:0天到24个月

MACCE 被定义为以下各项的组合:

  • 全因死亡
  • 心肌梗塞 (MI)
  • 所有中风,和
  • 再介入(定义为任何心脏手术或经皮再介入导管手术,用于修复、改变或调整或更换先前植入的瓣膜)
0天到24个月
Device Success as Defined in the Description.
大体时间:after procedure or discharge

The following components must be satisfied for device success:

  1. successful vascular access, delivery and deployment of device and successful retrieval of delivery system
  2. correct position of device in the proper anatomical location
  3. EOA≥1.0 cm² AND mean gradient <20 mmHg or peak velocity <3 m/s, without moderate or severe AR
  4. only one valve implanted.
after procedure or discharge
Procedural Success, Defined as Device Success and Absence of In-hospital MACCE
大体时间:from admission for procedure to discharge
Procedural success is defined as device success and absence of in-hospital MACCE.
from admission for procedure to discharge
人工瓣膜性能的超声心动图评估 - 平均梯度
大体时间:30天
30天
Echocardiographic Assessment of Prosthetic Valve Performance - Mean Gradient
大体时间:6 months
6 months
人工瓣膜性能的超声心动图评估 - 平均梯度
大体时间:12个月
12个月
人工瓣膜性能的超声心动图评估 - 平均梯度
大体时间:24个月
24个月
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
大体时间:30 days
30 days
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
大体时间:6 months
6 months
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
大体时间:12 months
12 months
Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)
大体时间:24 months
24 months
人工瓣膜性能的超声心动图评估 - 左心室射血分数 (LVEF)
大体时间:30天
30天
人工瓣膜性能的超声心动图评估 - 左心室射血分数 (LVEF)
大体时间:6个月
6个月
人工瓣膜性能的超声心动图评估 - 左心室射血分数 (LVEF)
大体时间:12个月
12个月
人工瓣膜性能的超声心动图评估 - 左心室射血分数 (LVEF)
大体时间:24个月
24个月
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
大体时间:30 days
30 days
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
大体时间:6 months
6 months
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
大体时间:12 months
12 months
Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)
大体时间:24 months
24 months
重复住院
大体时间:0天到30天
0天到30天
重复住院
大体时间:0天至6个月
0天至6个月
重复住院
大体时间:0天到12个月
0天到12个月
重复住院
大体时间:0天到24个月
0天到24个月
瓣膜相关死亡
大体时间:0天到30天
0天到30天
瓣膜相关死亡
大体时间:0天至6个月
0天至6个月
Valve-related Deaths
大体时间:0 day to 12 months
0 day to 12 months
瓣膜相关死亡
大体时间:0天到24个月
0天到24个月
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
大体时间:Baseline to 30 days
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status. The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population. The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score. Norm-based score is then derived as fifty plus 10 times of the z-score. A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
Baseline to 30 days
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
大体时间:Baseline to 6 months
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status. The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population. The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score. Norm-based score is then derived as fifty plus 10 times of the z-score. A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
Baseline to 6 months
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
大体时间:Baseline to 12 months
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status. The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population. The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score. Norm-based score is then derived as fifty plus 10 times of the z-score. A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
Baseline to 12 months
Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)
大体时间:Baseline to 24 months
The SF-36 assessment was used to evaluate subject Quality of life (QoL) by assessing change in physical function and general health status. The SF-36 v2 ͭ ͫ Scoring Program was used to convert raw scores ranging from 0 to 100 into norm-based scores, allowing direct comparison to the reference values for the Japanese population. The Z-score of each subdomain is calculated as the numbers of standard deviation away from the Japanese population mean of the corresponding raw score. Norm-based score is then derived as fifty plus 10 times of the z-score. A norm-based score of less than 50 was interpreted as below average when compared to the Japanese population whereas norm-based scores greater than 50 were interpreted as above average.
Baseline to 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yoshi Sawa, Professor、Osaka University Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年7月1日

初级完成 (实际的)

2014年2月1日

研究完成 (实际的)

2019年9月1日

研究注册日期

首次提交

2012年7月2日

首先提交符合 QC 标准的

2012年7月2日

首次发布 (估计)

2012年7月6日

研究记录更新

最后更新发布 (实际的)

2019年10月15日

上次提交的符合 QC 标准的更新

2019年10月7日

最后验证

2019年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅